• Radiother Oncol · Jul 2009

    Comparative Study

    Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.

    • Iskandar Kassim, Maarten L P Dirkx, and Ben J M Heijmen.
    • Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
    • Radiother Oncol. 2009 Jul 1; 92 (1): 62-7.

    PurposeIn dose escalation trial, for prostate cancer patients, zero CTV-PTV margins towards the rectum are often applied in the boost phase in order to avoid excessive dose delivery to the rectum. In this study, the dosimetric impact of non-exclusion of the rectum from the boost PTV is evaluated. Treatment plans created according to the protocol used in our institute for patients in a Dutch hypofractionated trial (HYPO), where the rectum is excluded from the boost PTV, were compared to plans designed with a modified version of this protocol (HYPO-exp) for which the rectal exclusion was not performed. Differences in target coverage and rectum dose were quantified.Methods And MaterialsTreatment plans were generated for 36 prostate cancer patients. In the HYPO plans, the CTV-PTV margins around the prostate were 6 mm (7.5 mm at the caudal side) and 10 mm around the seminal vesicles (PTV1). For the boost phase, these margins were reduced to 5 mm, but no margin was taken at the overlap with the rectum (PTV2). The margin prescription for HYPO-exp was identical to that for HYPO, except that the zero CTV-PTV margin towards the rectum was omitted. For the HYPO and HYPO-exp plans, a simultaneous integrated boost technique using IMRT was applied to deliver 72.2 Gy to PTV1 and 78 Gy to PTV2. For all plans, the dose to the rectum was compared using V(50), V(60), V(70), the equivalent uniform dose (EUD), considering alpha=9 and 1, respectively, and normal tissue complication probabilities (NTCPs). In addition, the dose coverage of PTV1 and PTV2 and the minimum dose in those volumes were quantified. To assess the clinical impact of differences in dose delivery to the rectum, both IMRT plans were also compared to a plan (DESC) based on the treatment protocol applied in our institute in a former national dose escalation trial, which in the meantime has a median follow-up of six years.ResultsCompared to HYPO, V(70) and the rectal EUD calculated with alpha=9 were slightly higher for HYPO-exp, but the differences were not statistically significant. V(50), V(60) and the rectal EUD calculated with alpha=1 were similar for both the IMRT plans. In contrast, each of these parameters was significantly lower compared to DESC (p<0.001). The coverage of the boost PTV, used in HYPO-exp, by at least 95% of the prescribed dose was significantly better for HYPO-exp than for HYPO (p<0.001). In the overlap of this volume with the rectum, the minimum dose increased by 1.1+/-1.2 Gy for HYPO-exp (p=0.002) and the mean dose by 1.2+/-1.5 Gy (p=0.001).ConclusionBy omitting the zero margin towards the rectum, underdosages in the target volume are reduced significantly, while a clinically relevant increase in rectum exposure is not observed.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,694,794 articles already indexed!

We guarantee your privacy. Your email address will not be shared.